Answers are grounded in this paper and cite their sources.
Case report shows a healthy full-term birth following early tofacitinib cessation in ulcerative colitis, suggesting reassuring outcomes for accidental first-trimester drug exposure.
Key Clinical Message Tofacitinib is contraindicated in pregnancy. We present a patient with ulcerative colitis on tofacitinib who had an unplanned pregnancy. Tofacitinib was ceased, switched to vedolizumab, and she gave birth to a healthy newborn at term. Case reports of reassuring outcomes provide real‐world data that assists decision‐making for future patients.
No takes yet. Share an insight, caveat, or question.
Arzivian et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: